Specific Objectives

The remit and detailed objectives of ACCELERATE have been described in “Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer”:

  • To accelerate science driven development of paediatric oncology drugs
  • To facilitate international cooperation and collaboration between all stakeholders
  • To improve early access to new anticancer drugs in development for children and adolescents
  • To set-up long-term follow-up (LTFU) of children and adolescents exposed to new drugs

Within the international regulatory environment, the 4 priorities are:

  1. Paediatric development of an oncology drug should be based on its mechanism-of-action rather than its adult indication
  2. Prioritisation of oncology drugs should be established in order to match rare and frail children with cancer to the best available therapies
  3. Reduction in the delays in starting the paediatric development of potentially life-saving innovative drugs
  4. Implement more effective and flexible rewards to better incentivize the development of new specific paediatric medicines

 

More Information:

Article ‘Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer’, G. Vassal et al., European Journal of Cancer, Volume 51, Issue 2, 218 – 224

Summary of the article ‘Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer’

Table (extract from ‘Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer’)



For more information, please contact contact@accelerate-platform.eu
You can tweet using #ACCELERATEPlatform